Recurrence Risk Evaluation by 21-gene Detection
Recurrence Risk Evaluation by 21-gene Detection
Breast cancer patients with early breast cancer were enrolled according to the inclusion
 criteria. Baseline characteristics were recorded from medical record system. Recurrence score
 were obtained by 21-gene detection kits from different biological companies. Relationship
 between recurrence score and the prognosis was explored. Meanwhile, the investigators
 analyzed the consistency of the results obtained from various 21-gene test kits and
 immunohistochemistry detection.
Inclusion Criteria:

 1. breast cancer in stage I-III, tumor size>0.5cm

 2. lymph nodes negative

 3. hormone receptor positive （ER+/PR+,ER+/PR-,ER-/PR+）

 4. HER2 negative（IHC 0 or +， FISH negative）

 5. receive endocrine therapy only

 6. enough FFPE samples within 10 years（3~6 10μm ）

 7. patients with integrated medical records

 Exclusion Criteria:

 1. Tumor cells <5%

 2. Isolated RNA<500ng